Long-term statin use in patients with lung cancer and dyslipidemia reduces the risk of death
Metrics: PDF 1173 views | HTML 1197 views | ?
Wen-Yen Huang1,2, Chia-Hsiang Li3, Cheng-Li Lin4,5, Ji-An Liang6,7
1Department of Radiation Oncology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
2Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan
3Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan
4Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan
5College of Medicine, China Medical University, Taichung, Taiwan
6Graduate Institute of Clinical Medical Science, College of Medicine, China Medical University, Taichung, Taiwan
7Department of Radiation Oncology, China Medical University Hospital, Taichung, Taiwan
Ji-An Liang, email: email@example.com
Keywords: lung cancer, statin, population-based case-control study
Received: March 15, 2016 Accepted: May 20, 2016 Published: June 07, 2016
Background: Clinical studies have obtained inconsistent results of statin use on cancer outcomes. This study investigated the association between statin use and lung cancer mortality.
Results: The use of statin decreased mortality (hazard ratio = 0.91; 95% confidence interval: 0.86–0.96; P < .01). The patients with a high cumulative defined daily dose of statin use before lung cancer diagnosis exhibited a low risk of mortality.
Materials and Methods: We conducted a population-based case-control study of patients with dyslipidemia. Among them, 6270 had used statins for at least 3 months before lung cancer diagnosis, and 6270 had never used statins.
Conclusions: We found that statin use can reduce lung cancer mortality. A further prospective study is necessary to confirm these findings.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.